Among them, treatments with IFNs are generating promising outcomes, particularly in early stages of infection (13, 14), supporting that IFNs and IFN responses can serve as key antiviral tools for early therapeutic COVID-19 interventions. This evidence concerns the gene IFNA1 and COVID-19.